Generation of dendritic cells ex vivo: Differences in steady state versus mobilized blood from patients with breast cancer, with lymphoma, and from normal donors

Journal of Hematotherapy and Stem Cell Research

Volumn 10, Issue 5, 2001, Pages 621-630

  Syme, R M ^a   Duggan, P ^b   Stewart, D ^a   Gluck S ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b Health Sciences Centre St John's   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERLEUKIN 4; METHOTREXATE;

ADULT; APHERESIS; ARTICLE; BIOLOGICAL THERAPY; BLOOD DONOR; BREAST CANCER; CANCER CHEMOTHERAPY; CELL CULTURE; CELL FUNCTION; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOMA; MALE; MIXED LYMPHOCYTE REACTION; MONONUCLEAR CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ADULT; AGED; ANTIGENS, CD14; ANTIGENS, CD34; BREAST NEOPLASMS; CELL COUNT; DENDRITIC CELLS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; INTERLEUKIN-4; LEUKAPHERESIS; LEUKOCYTES, MONONUCLEAR; LYMPHOMA; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED;

EID: 0034779752     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/152581601753193832     Document Type: Article

References (32)

1. Soluble CD4, soluble CD8, soluble CD25, lymphopoieitic recovery, and endogenous cytokines after high-dose chemotherapy and blood stem cell transplantation
2. Minimal residual disease in solid tumor malignancies: A review
3. The dendritic cell system and its role in immunogenicity
4. + cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells
5. Dendritic cells and the control of immunity
6. Human dendritic cells
7. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α
8. Proliferating dendritic cell progenitors in human blood
9. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application
10. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
11. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: Implications for live kidney cancer vaccines
12. In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy
13. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
14. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
15. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
16. A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy
17. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimes
18. + cell dose
19. Development and function of dendritic cells in health and disease
20. + blood dendritic cells
21. Expansion of immunostimulatory dendritic cells from peripheral blood of patients with cancer
22. Identification of potent mixed leukocyte reaction-stimulatory cells in human bone marrow. Putative differentiation stage of human blood dendritic cells
23. + Th1 and Th2 cells by blood dendritic cells
24. Effects of cytokines on the culture and differentiation of dendritic cells in vitro
25. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells
26. Multidimensional flow-cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients
27. Decreased antigen presentation by dendritic cells in patients with breast cancer
28. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five-year results
29. Is high-dose better that standard-dose chemotherapy as initial treatment of poor-risk large-cell lymphomas? A critical analysis from available randomized trials
30. In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo therapy
31. Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors
32. Generation of dendritic cells from adherent cells of cord blood by culture with granulocyte-macrophage colony stimulating factor, interleukin-4 and tumor necrosis factor-α